Hydrochloride, Nogitecan | Health Canada Patents | Expiry | Expiration | Dates | PharmaCompass.com

Please Wait

Applying Filters...

Grow Your Pharma Business Digitally

Find Suppliers : API/FDF
- Search Our Integrated Database
Services
Excipients
CDMO Prospector
- Demo Dashboard
Drugs in Dev.
News
Blog
Market Place
Login

Hydrochloride, Nogitecan
Health Canada Patents

AMI Lifesciences is Driven by Chemistry. Powered by People.

Contact Supplier

Polpharma is a Polish CDMO of APIs and a significant European API producer, delivering products to companies worldwide.

Contact Supplier

Bhavna Laboratories is an API & Intermediate manufacturer focusing on the muscle relaxant & ophthalmic segments.

Contact Supplier

Zach System is committed to providing Highly Customized Solutions for all your Development Programs.

Contact Supplier

Quotient Sciences- Molecule to Cure. Fast.

Contact Supplier

pharmacompass-2-m-2025-08-25

Hydrochloride, Nogitecan

ACCESS ALL DATA, CHEMISTRY

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

19 API Suppliers, 6 USDMF, 1 JDMF, 4 KDMF, 3 NDC API, 12 Listed Suppliers, $ API Reference Price

19 API Suppliers
6 USDMF
1 JDMF
4 KDMF
3 NDC API
12 Listed Suppliers
$ API Reference Price

DEVELOPMENTS

76 Drugs in Development

76 Drugs in Development

INTERMEDIATES

3 Intermediate Suppliers

3 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

72 FDF Dossiers, 22 FDA Orange Book, 31 Europe, 5 Canada, 4 Australia, 4 South Africa, 6 Listed Dossiers

72 FDF Dossiers
22 FDA Orange Book
31 Europe
5 Canada
4 Australia
4 South Africa
6 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

SOLUTION;INTRAVENOUS - EQ 1MG BASE/ML (EQ 1MG BASE/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, SOLUTION;INTRAVENOUS - EQ 3MG BASE/3ML (EQ 1MG BASE/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, SOLUTION;INTRAVENOUS - EQ 4MG BASE/4ML (EQ 1MG BASE/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, SOLUTION;INTRAVENOUS - EQ 4MG BASE/4ML (EQ 1MG BASE/ML), INJECTABLE;INJECTION - EQ 4MG BASE/VIAL, CAPSULE;ORAL - EQ 0.25MG BASE, CAPSULE;ORAL - EQ 1MG BASE

SOLUTION;INTRAVENOUS - EQ 1MG BASE/ML (EQ 1MG BASE/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
SOLUTION;INTRAVENOUS - EQ 3MG BASE/3ML (EQ 1MG BASE/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
SOLUTION;INTRAVENOUS - EQ 4MG BASE/4ML (EQ 1MG BASE/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
SOLUTION;INTRAVENOUS - EQ 4MG BASE/4ML (EQ 1MG BASE/ML)
INJECTABLE;INJECTION - EQ 4MG BASE/VIAL
CAPSULE;ORAL - EQ 0.25MG BASE
CAPSULE;ORAL - EQ 1MG BASE

RELATED EXCIPIENT COMPANIES

1 Rochem International Inc, 14 SPI Pharma, 6 DKSH, 1 Gangwal Healthcare, 1 Pfanstiehl, 1 Capital Farma, 4 ACG Worldwide, 1 Actylis, 2 BASF, 1 CD Formulation, 3 Gangwal Chemicals, 1 Ingredion Pharma Solutions, 1 Kerry, 3 Lonza Capsugel, 2 Microlex e.U, 1 Pluviaendo, 1 Qualicaps, 5 Roquette, 1 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 1 Shijiazhuang Huaxu Pharmaceutical, 1 Sigachi Industries

1 Rochem International Inc
14 SPI Pharma
6 DKSH
1 Gangwal Healthcare
1 Pfanstiehl
1 Capital Farma
4 ACG Worldwide
1 Actylis
2 BASF
1 CD Formulation
3 Gangwal Chemicals
1 Ingredion Pharma Solutions
1 Kerry
3 Lonza Capsugel
2 Microlex e.U
1 Pluviaendo
1 Qualicaps
5 Roquette
1 Shanghai Shenmei Pharmaceutical Technology Co., Ltd
1 Shijiazhuang Huaxu Pharmaceutical
1 Sigachi Industries

EXCIPIENTS BY APPLICATIONS

21 Fillers, Diluents & Binders, 12 Chewable & Orodispersible Aids, 11 Taste Masking, 10 Direct Compression, 8 Empty Capsules, 7 Disintegrants & Superdisintegrants, 6 Coating Systems & Additives, 6 Thickeners and Stabilizers, 5 Parenteral, 5 Solubilizers, 3 Granulation, 3 Co-Processed Excipients, 2 Topical, 2 Coloring Agents, 2 Film Formers & Plasticizers, 1 Controlled & Modified Release

21 Fillers, Diluents & Binders
12 Chewable & Orodispersible Aids
11 Taste Masking
10 Direct Compression
8 Empty Capsules
7 Disintegrants & Superdisintegrants
6 Coating Systems & Additives
6 Thickeners and Stabilizers
5 Parenteral
5 Solubilizers
3 Granulation
3 Co-Processed Excipients
2 Topical
2 Coloring Agents
2 Film Formers & Plasticizers
1 Controlled & Modified Release

DIGITAL CONTENT

1 Data Compilation #PharmaFlow, 21 News #PharmaBuzz

1 Data Compilation #PharmaFlow
21 News #PharmaBuzz

GLOBAL SALES INFORMATION

4 US Medicaid Prescriptions, 20 Regulatory FDF Prices

4 US Medicaid Prescriptions
20 Regulatory FDF Prices

MARKET PLACE

5 APIs, 5 FDF Dossiers

5 APIs
5 FDF Dossiers

PATENTS & EXCLUSIVITIES

2 Health Canada Patents

2 Health Canada Patents

REF. STANDARDS & IMPURITIES

1 Others

1 Others

$ API Ref.Price (USD/KG) : 757,716 Xls

Filters

Reset all filters

Filters

FILTER :

filter Company Reset all filters

2 All

01 2GlaxoSmithKline Inc.

filter Patent Reset all filters

2 All

01 12103707

02 12103708

filter Product Reset all filters

2 All

01 2Topotecan Hydrochloride

filter Dosage Reset all filters

2 All

01 2Sterile lyophilized Powder in single dose vials

filter Exp Date Reset all filters

2 All

01 22012-02-07

Product Main Page

01

GlaxoSmithKline Inc.

Topotecan Hydrochloride

CPHI Shenzhen

Not Confirmed

GlaxoSmithKline Inc.

CPHI Shenzhen

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2012-02-07

Date Granted : 2003-12-09

Topotecan Hydrochloride

Brand Name : HYCAMTIN

Patent Number : 2103707

Filing Date : 1992-02-07

Strength per Unit : 4mg as free base per vial

Dosage Form : Sterile lyophilized Powder in single dose vials

Human Or VET : Human

Route of Administration : Intravenous Administration

Patent Expiration Date : 2012-02-07

Date Granted : 2003-12-09

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

02

GlaxoSmithKline Inc.

Topotecan Hydrochloride

CPHI Shenzhen

Not Confirmed

GlaxoSmithKline Inc.

CPHI Shenzhen

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2012-02-07

Date Granted : 2004-04-27

Topotecan Hydrochloride

Brand Name : HYCAMTIN

Patent Number : 2103708

Filing Date : 1992-02-07

Strength per Unit : 4mg as free base per vial

Dosage Form : Sterile lyophilized Powder in single dose vials

Human Or VET : Human

Route of Administration : Intravenous Administration

Patent Expiration Date : 2012-02-07

Date Granted : 2004-04-27

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

Contact us
to update this info

Privacy policy
Terms and conditions
Disclaimers
Ask Us!